The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
On a side note, great news for developing nations vaccination rates and novavax today passing phase 3 trial in the us and mexico.They've certainly come a long way.
'Novavax on Monday said a late-stage trial of its coronavirus vaccine found it was effective, an encouraging sign that there would be further doses of a medication to fight the pandemic.
Novavax said its Phase 3 trial of nearly 30,000 patients in the U.S. and Mexico found the vaccine was 90.4% effective overall and was 100% effective in protecting against moderate and severe disease.
The company said it intends to file for regulatory approval in the third quarter, and that it is on track to reach manufacturing capacity of 100 million doses by the end of the third quarter. In early June, Novavax said the trial results would be announced before the end of the month.
Novavax Chief Executive Stanley Erck told the Associated Press that many of its first doses will go to low- and middle-income countries. While more than half of the U.S. population has received at least one COVID-10 vaccine dose, less than 1% of people in the developing world have, the AP report said.'
'Westminster Hour' last evening - arguing gently against suspending patent protections on Covid IP, a comment from Damien Green MP - prescient ?
" . . . . maybe something else is coming down the track that we haven't even thought about yet".
I certainly hope so Mr Green !!
23 minutes in https://www.bbc.co.uk/sounds/play/m000wyxd
Krafty - post rec. Yes if Prof. Lindy still has 'Covidity' on track it would be astounding if it failed to generate all sorts of interest. Govt's, Pharma and the likes of CEPI. But as ever, the wait goes on. So that's a tick tock then.
TF. On the basis there was a very short timeline to prepare the bid for money and the continual retweeting of this article it would be very cruel if Scancell was not one of the recipients of the funding. It is simple logic that killing the core of the virus, the N protein by for example using the immunobody technology is the only way to beat mutations and there will be a mutation one day that evades the S protein as the Delta variant has threatened to do. The effect of Cepi involvement for Novavax led to an increase in SP for a Covid vaccine alone, equivalent for us peaking at £3, settling at £2. Add Immunobody, moditope and everything else is why I asked a couple of weeks ago what would people be happy with if a trade sale took place. All speculation of course for now, but it is based on what we all know.
CEPI retweeted again ! 'Pick the bones out' as you say RW . . .
So, since March 1st, Scancell and Caltech are 'mentioned' (repeatedly) as hunters of the universal vax. It's evident too, that the need for a 'Universal' vax has become ever more critical as the variants march on. " . . . . . scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses." https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/
CEPI retweeted again ! 'Pick the bones out' as you say RW . . .
So, since March 1st, Scancell and Caltech are 'mentioned' (repeatedly) as hunters of the universal vax. It's evident too, that the need for a 'Universal' vax has become ever more critical as the variants march on. " . . . . . scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses." https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/
I was pondering about how the reaction of some on the board would be if the CEPI tweet had a different company name, and anyone suggested Scancell could be in with a shout for CEPI support. That would be an interesting one to see. But the plain fact is that while it is no guarantee until news comes, SCLP have been at the forefront of an article that CEPI have retweeted on several recent occasions. So pick the bones out of that, as they say.
Time will tell....
Hi miavoce
CEPI is a large organisation so anything they promote is not mentioned by chance. To continually tweet out their message and not adjust the paragraph on Nottingham Uni and Scancell must mean that to CEPI that the acknowledgement is still very relevent.
Plus over the many months no other proposed platform has supplanted the choice of Covidity.
It has to add up to something !!
Chester.
CEPI just tweeted the March article again which mentions Scancell.....hopefully they are now putting their money where their tweets are.
https://twitter.com/CEPIvaccines/status/1404076343021670402